MedPath

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center logo
🇺🇸United States
Ownership
Private
Established
1884-01-01
Employees
10K
Market Cap
-
Website
http://www.mskcc.org

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Phase 1
Completed
Conditions
Leukemia
Lymphoma
Interventions
Biological: filgrastim
Biological: pegfilgrastim
Biological: rituximab
Biological: sargramostim
Drug: cyclophosphamide
Drug: mitoxantrone hydrochloride
Drug: pentostatin
Genetic: fluorescence in situ hybridization
Genetic: gene rearrangement analysis
Genetic: polymerase chain reaction
Genetic: protein expression analysis
Other: flow cytometry
Procedure: biopsy
First Posted Date
2007-10-18
Last Posted Date
2016-05-12
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
50
Registration Number
NCT00546377
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

Phase 2
Completed
Conditions
Lymphoma
Leukemia
Interventions
First Posted Date
2007-10-08
Last Posted Date
2017-08-11
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
49
Registration Number
NCT00541034
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Trial of Beads Versus Doxorubicin Eluting Beads for Arterial Embolization of Hepatocellular Carcinoma

Phase 2
Completed
Conditions
Liver Cancer
Hepatocellular Carcinoma
Hepatoma
Interventions
Device: Bead Block microspheres
Other: Bead + Dox Arm
First Posted Date
2007-10-04
Last Posted Date
2023-08-18
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
101
Registration Number
NCT00539643
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Gemcitabine and Oxaliplatin in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Phase 2
Completed
Conditions
Pancreatic Cancer
Interventions
Drug: gemcitabine hydrochloride
Drug: oxaliplatin
Genetic: protein expression analysis
Genetic: proteomic profiling
Other: diagnostic laboratory biomarker analysis
Procedure: adjuvant therapy
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery
First Posted Date
2007-09-28
Last Posted Date
2017-03-16
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
39
Registration Number
NCT00536874
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure

Completed
Conditions
Psychosocial Effects of Cancer and Its Treatment
Head and Neck Cancer
Interventions
Other: questionnaire administration
Procedure: assessment of therapy complications
Procedure: psychosocial assessment and care
Procedure: quality-of-life assessment
First Posted Date
2007-09-17
Last Posted Date
2021-12-21
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
1745
Registration Number
NCT00530049
Locations
🇨🇦

McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada

🇺🇸

New School for Social Research, New York, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 1 locations

Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia

Phase 2
Terminated
Conditions
Leukemia
Interventions
First Posted Date
2007-09-12
Last Posted Date
2016-01-29
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
1
Registration Number
NCT00528450
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant

Phase 2
Completed
Conditions
Leukemia
Myelodysplastic Syndromes
Interventions
Biological: natural killer cell therapy
Drug: cyclophosphamide
Drug: fludarabine
First Posted Date
2007-09-10
Last Posted Date
2016-02-12
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
12
Registration Number
NCT00526292
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

Phase 2
Terminated
Conditions
Primary Peritoneal Cavity Cancer
Fallopian Tube Cancer
Ovarian Cancer
Interventions
Drug: sorafenib tosylate
Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: pharmacological study
First Posted Date
2007-08-29
Last Posted Date
2016-02-29
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
6
Registration Number
NCT00522301
Locations
🇺🇸

Memorial Sloan - Kettering Cancer Center, New York, New York, United States

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Phase 2
Completed
Conditions
Lymphoma
Interventions
Biological: filgrastim
Biological: rituximab
Biological: sargramostim
Drug: carmustine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: autologous hematopoietic stem cell transplantation
First Posted Date
2007-08-27
Last Posted Date
2015-12-22
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
14
Registration Number
NCT00521014
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Factors Affecting Decisions About Breast Reconstruction After Mastectomy in Black and Latina Women

Completed
Conditions
Psychosocial Effects of Cancer and Its Treatment
Breast Cancer
First Posted Date
2007-08-23
Last Posted Date
2015-10-01
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
55
Registration Number
NCT00519974
Locations
🇺🇸

New School for Social Research, New York, New York, United States

🇺🇸

SHARE, Incorporated, New York, New York, United States

🇺🇸

Ralph Lauren Center for Cancer Care and Prevention, New York, New York, United States

and more 3 locations
© Copyright 2025. All Rights Reserved by MedPath